Xiaofei M.,Tianjin Medical University |
Xiaofei M.,Key Laboratory of Cancer Immunology and Biotherapy of Tianjin |
Yaqin Q.,Tianjin Medical University |
Yaqin Q.,Key Laboratory of Cancer Immunology and Biotherapy of Tianjin |
And 8 more authors.
Chinese Journal of Cancer Biotherapy | Year: 2015
Objective: To evaluate changes in and prognostic value of CD8+ T cells in the peripheral blood of melanoma patients treated with GM-CSF modified tumor cell vaccine (GVAX). Methods: Fifty-six patients with melanoma who undement GVAX treatment in the Cancer Institute of Tianjing Medical University between October, 2007 and December, 2012 were enrolled in the study. Proportions of CD3+ lymphocytes，CD4+ T cells, CD8+ T cells, regulatory T lymphocytes (Treg), natural killer cells(NK) and dendritic cell (DC 1, DC 2) before and after GVAX vaccination treatment were detemiined by flow cytometry. The relationship between the proportion of CD8+ T cells and other immune cells with patient survival at different post-treatment time points was analyzed. Results: The proportion of CD8+ T cells in peripheral blood was significantly higher (P =0. 006) after GVAX treatment (37. 56 土 12. 16%) than that before the treatment (34. 71 土 12. 30%). GVAX treatment resulted in significant decreases in the proportion of CD4+ T cells (P =0. 017) and the ratio of CD4+/CD8+ (P = 0. 009) but showed no significant effect on the proportions of NK cells, Treg cells, DC1 and DC2 cells (P >0.05). Advanced melanoma patients with a proportion of CD8+ T cells above the mean value before vaccination had better overall survival (29. 16 months) compared with those with a lower proportion of CD8+ T cells (13. 34 months)(P=0. 012). Conclusion: GVAX can enhance the ability of CD8+T cells to induce antitumor immunity. A high proportion of CD8+T cells before GVAX vaccination is a predictor of better prognosis for patients with advanced melanoma. © 2015, Editorial office of Chinese Journal of Cancer Biotherapy. All rights reserved. Source